Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice-Reference-Cited by-同舟云学术

Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice

Published:2018-10 Issue:10 Volume:38 Page:2448-2459
ISSN:1079-5642
Container-title:Arteriosclerosis, Thrombosis, and Vascular Biology
language:en
Short-container-title:Arterioscler Thromb Vasc Biol.

Author:

Singh Amar Bahadur¹,Dong Bin¹,Kraemer Fredric B.¹²,Xu Yanyong³,Zhang Yanqiao³,Liu Jingwen¹

Affiliation:

1. From the Veterans Affairs Palo Alto Health Care System, CA (A.B.S., B.D., F.B.K., J.L.)

2. Department of Medicine, Stanford University, CA (F.B.K.)

3. Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown (Y.X., Y.Z.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference47 articles.

1. Hepatic Clearance of Plasma Low Density Lipoproteins

2. Statin Trials and Goals of Cholesterol-Lowering Therapy

3. Regulation of the mevalonate pathway

4. A Receptor-Mediated Pathway for Cholesterol Homeostasis

5. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melatonin-mediated corrective changes in gut microbiota of experimentally chronodisrupted C57BL/6J mice;Chronobiology International;2024-04

2. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor;Current Reviews in Clinical and Experimental Pharmacology;2023-10-05

3. RNA-binding proteins in vascular inflammation and atherosclerosis;Atherosclerosis;2023-06

4. Obeticholic Acid—A Pharmacological and Clinical Review;Future Pharmacology;2023-02-28

5. Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis;RPS Pharmacy and Pharmacology Reports;2022-09-01